Survodutide: The GLP-1/Glucagon Dual Agonist That Could Reshape Obesity and MASH Treatment
Survodutide targets both the GLP-1 and glucagon receptors — and its Phase 3 SYNCHRONIZE readout, expected any day in 2026, could reframe how we think about obesity treatment and metabolic liver disease.